In conclusion, we provide evidence that CXCR2 blockade inhibits senescence-associated, tumour-elicited myeloid inflammation, with this blockade reversing ARSI resistance to confer durable antitumour activity in a subset of patients with mCRPC. The gene discussed is CXCR2; the disease is neoplasm.